Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744471 | 0.91 | PTPN1 (0.53) | PTPN1NR1H2NR1H3HDAC8POLB | |
| SCHEMBL4598233 | 0.88 | ACE (0.41) | PTPN1HDAC8POLBKDM4EGPR119 | |
| SCHEMBL14097936 | 0.87 | PTPN1 (0.53) | PTPN1HDAC8POLBKDM4E | |
| SCHEMBL21490343 | 0.83 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8NAMPT | |
| SCHEMBL29443079 | 0.83 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8NAMPT | |
| SCHEMBL2737917 | 0.83 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8NAMPT | |
| SCHEMBL8189194 | 0.79 | NAMPT (0.40) | PTPN1NR1H2NR1H3MAPK1NAMPT | |
| SCHEMBL4597855 | 0.79 | HDAC8 (0.43) | PTPN1HDAC8POLBKDM4EGPR119 | |
| SCHEMBL17094830 | 0.79 | PTPN1 (0.42) | PTPN1NR1H2NR1H3POLBKDM4E | |
| SCHEMBL14097934 | 0.78 | PTPN1 (0.53) | PTPN1HDAC8POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | PTPN1 769/4885NR1H2 459/4885NR1H3 435/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | PTPN1 769/4885NR1H2 459/4885NR1H3 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.